NeoGenomics Inc. Common Stock vs ZIM Integrated Shipping Services Ltd — how do they compare? NeoGenomics Inc. Common Stock trades at $16.85 (market cap $2.14B), while ZIM Integrated Shipping Services Ltd trades at $29.84 (market cap $3.67B). The key difference: ZIM Integrated Shipping Services Ltd is the larger of the two by market cap, and ZIM Integrated Shipping Services Ltd pays a 20.16% dividend while NeoGenomics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold NeoGenomics Inc. Common Stock for 0 Days and ZIM Integrated Shipping Services Ltd for 23 Days on average.
| NEO | ZIM | |
|---|---|---|
Market Cap | $2.14B | $3.67B |
Volume | 2,228,400 | 1,172,596 |
Sector | Health | Industrials |
52-Week High | $19.91 | $30.90 |
52-Week Low | $7.19 | $13.32 |
Typical Hold Time | 0 Days | 23 Days |
Enterprise Value | $2.44B | $7.34B |
Dividend Yield | — | 20.16% |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
ZIM trades at $30.43, down 1.52% on the day, with a bullish technical signal from moving averages. The stock is near its 52-week high of $30.96, reflecting strong momentum. Fundamentally, Q2 2026 earnings of $0.53 per share significantly beat expectations, driven by a 9% revenue increase to $1.8 billion, though full-year 2026 guidance indicates margin pressure. The pending $35 per share acquisition offer from Hapag-Lloyd, subject to Israeli government approval, creates a key near-term catalyst.
The investment case balances potential upside from the acquisition against operational risks. If approved, the deal offers immediate premium; if rejected, ZIM's standalone value hinges on sustaining high transpacific freight rates. Analyst sentiment is cautious with no buy ratings, highlighting execution and geopolitical risks. The stock presents a speculative opportunity with binary outcomes centered on the merger decision.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
NeoGenomics, Inc. is a US cancer diagnostics company that provides genomic and pathology testing services, offering an oncology-focused testing menu used by oncologists, pathologists, and hospital systems across the cancer care continuum.
Read more on NEO →ZIM is a global container liner shipping company that employs a 'global-niche' strategy, focusing on specific trade lanes where it holds a competitive advantage. Unlike larger, asset-heavy competitors, ZIM operates an agile, charter-intensive fleet, allowing it to rapidly adjust capacity to market demand while prioritizing digitalization and specialized cargo like refrigerated (reefer) goods.
Read more on ZIM →